Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of ruxolitinib plus corticosteroids for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
ChiCTR2000031618Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib and corticosteroids in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Peking University People's Hospital. Primary endpoint: Overall response rate at 7 days. Started Jun 2020; status: recruiting.
02
Drugs
ruxolitinibcorticosteroids
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2000031618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031618.